UCB (EBR:UCB) UCB Media Room: Disposals of own shares
Transparency directive : regulatory news
10/11/2020 20:04
https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513=
9PTmAm2ORJ-2Fb7C-2B6ekhh2n-2BRHUCD1FxRCCkPnsgT-2BAkQWpd5DxMs8GAkN6qIeP7Wktq=
GyStJACxWLGbv1sUAaIDbKhlaeEjErspVQuns1nx_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVW=
u7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9=
g1wZEMZIHLafUIJL9IDButNVPltWMkFZCqcbfB7v6fXW0JW2ygGf2FYUXzy-2BAgRwQB-2BlDDi=
7B3TyL6dEl4SpM8RZYXQtsXSvkZU-2F4lZhuRWDVxnhp5TorPzrk4jyfQIJBZg9JtcQOz-2ByDW=
DR8LgLN8RKYqS3Ve1Iu-2FIgV5-2FaFww483ffnX0f6QhK8PTaxA9c1w4y2FIDE0q6fypwUZ3VL=
EeHpp2NFi9C7G0DhtZVXlsvLmQC0Q6a1O-2BlVkKnIz-2BACWHg-3D
** Disposals of own shares
------------------------------------------------------------
Brussels (Belgium), 10 November 2020 =E2=80=93 20:00 (CET) =E2=80=93 regula=
ted information
In accordance with article 8:6 of the Royal Decree executing the Belgian Co=
de of Companies and Associations, UCB SA/NV (=E2=80=9CUCB=E2=80=9D or the =
=E2=80=9CCompany) (Euronext Brussels: UCB) announces that, following exerci=
ses of stock options by members of its personnel, it has disposed of UCB sh=
ares OTC in view of deliveries of these shares to the relevant members of t=
he personnel, within the framework of the Long Term Incentive Program of th=
e UCB Group, as follows:
https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513=
9PTmAm2ORJ-2Fb7C-2B6ekhh2n-2BRHUCD1FxRCCkPnsgZvw-2FyG-2FrJkkfs5hAhIo61KEo0l=
mUo7uF9-2FIh9TxBQxMocJ65TxJ24KR7DN4xHkhvKlVu_xDPID0vOuylFAU8fv4e60wei4JxqEG=
BdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2=
X9c9g1wZEMZIHLafUIJL9IDButNVPltWMkFZCqcbfB7v6fXW0JW2ygGf2FYUXzy-2BAgRwQB-2B=
lDDi7B3TyL6dEl4SpM8RZYXQtsXSvkZU-2F4lZhuRWDVxtYal571pG9-2Fq0lWwAGBqoxeH0N3Y=
wqSaFXPhK-2FiHh6C-2FocDmo9O4G8eBzuGGHYRJsn-2FCNCGAmLk7gGIhYwEEPy5SEyQBQVdQw=
Ve3hPutTsir0b8C-2FzdWx5pjBUpzS8kHFQKqpjuYHeIf9nqWodPnfk-3D
=C2=A0
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQ=
yQ53jATUXZJD59ZUodhGC-2FyJVE-2BjXw-2Fd0j1C70r-2FZ058zOLCiGbx-2FzvKhSzxYKNx1=
8dK5MiuQ-3D-3DF6MD_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bS=
l0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZEMZIHLafUIJL9IDBut=
NVPltWMkFZCqcbfB7v6fXW0JW2ygGf2FYUXzy-2BAgRwQB-2BlDDi7B3TyL6dEl4SpM8RZYXQts=
XSvkZU-2F4lZhuRWDVxtn8r5fTQhTShPd8XrzXhRI2hjQmHO9D2PagJNMU-2BwlSYeJYoj50Xua=
-2FZGjjlLpJmRMt8B-2FHVyY8V9ByIW6Hu2NQ9jqDr0zHglwQQFVSmDteyQ8i7IZ-2FVUEqRVLO=
I6ZSM4YQrY0zxT6W-2B27v3m5Lvhs-3D .
Investor Relations
Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com
Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With 7 500 people in approxima=
tely 40 countries, the company generated revenue of =E2=82=AC 4.9 billion i=
n 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twit=
ter: @UCB_news
=C2=A0
GenericFile
201110 - Disposals of own shares (https://u7061146.ct.sendgrid.net/ls/click=
?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6ekhh2n-2BRHUCD1FxRCCk=
PnsgQ3X0Ata59CC8e4b2AtqZJ-2Fk7iEphanZiOTR4rO1VcTw-3D3u_c_xDPID0vOuylFAU8fv4=
e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCO=
G9ekocVj-2F2X9c9g1wZEMZIHLafUIJL9IDButNVPltWMkFZCqcbfB7v6fXW0JW2ygGf2FYUXzy=
-2BAgRwQB-2BlDDi7B3TyL6dEl4SpM8RZYXQtsXSvkZU-2F4lZhuRWDVxlY4ngB6Tbto2ngMHbK=
KezfQoloiA92inZ4y0qrSCSBYT4Ex8HjmVjILPas1dRTGAbOoJCRUEDI6LEA6nFHkNcBPp-2F8G=
7g3xebx1MHmcVU29zCuAxHr19V6I7pH9PV5KHsOaYPoXV-2F0dTdPZlymaYJc-3D GenericFile
201110 - Ali=C3=A9nation d actions propres (https://u7061146.ct.sendgrid.ne=
t/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6ekhh2n-2BRH=
UCD1FxRCCkPnsgaqjzBcDY8LUnwP-2B1tBwa1vp4ZhS-2F2Q6Ji-2FBDaaFccsU-3DNpkq_xDPI=
D0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlG=
B52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZEMZIHLafUIJL9IDButNVPltWMkFZCqcbfB7v6fXW0=
JW2ygGf2FYUXzy-2BAgRwQB-2BlDDi7B3TyL6dEl4SpM8RZYXQtsXSvkZU-2F4lZhuRWDVxgKxz=
HUfV-2FVPfDhrDAFGlaS0bNFwfz3c27yH0WzFpzWFhD2XO5qatcSOuRvDRD3w2VBBGkcQCOfcrL=
ukeOUzudswUYU5SLm64zJ4mEZmK0bhPQTejTd88jSIPbK0M-2F7ohfRzXflRHrP8pgp6giczaII=
-3D GenericFile
201110 - Vervreemding van eigen aandelen (https://u7061146.ct.sendgrid.net/=
ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6ekhh2n-2BRHUC=
D1FxRCCkPnsg1kEPbdxZuZFt40UAYA1jaRXR-2FNQD8JszmMmN03noEd0-3DsX-O_xDPID0vOuy=
lFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf=
-2FOeoCOG9ekocVj-2F2X9c9g1wZEMZIHLafUIJL9IDButNVPltWMkFZCqcbfB7v6fXW0JW2ygG=
f2FYUXzy-2BAgRwQB-2BlDDi7B3TyL6dEl4SpM8RZYXQtsXSvkZU-2F4lZhuRWDVxkpQB-2Flj9=
mo7mrBAUsuvoqhShRU-2FGghwaC4eH2I3G2dAlMejSomAeLOsuXqUKj-2BRJVPDP4oaFtwA-2BD=
wLX5MGM7MQCynMZL2MILwaz7sNDLIH1ACx5ZZjxOORqpwgNYxsAueOgDclq9A5iQECyl7G4hw-3=
D Image
Chart 1 Nov 10 2020 (https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-=
2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6ekhh2n-2BRHUCD1FxRCCkPnsgZvw-2FyG-=
2FrJkkfs5hAhIo61HDj609YXrb-2FkZFXq0J3zw4-3D4NLW_xDPID0vOuylFAU8fv4e60wei4Jx=
qEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-=
2F2X9c9g1wZEMZIHLafUIJL9IDButNVPltWMkFZCqcbfB7v6fXW0JW2ygGf2FYUXzy-2BAgRwQB=
-2BlDDi7B3TyL6dEl4SpM8RZYXQtsXSvkZU-2F4lZhuRWDVxiRifKpgc8F2t4mJjbNdKltGhiGI=
uRmzDBIrW-2FL3Z4NL59V6UOZQL-2BU7qui-2BjxHJ0RlLgfAy5TF0M-2FnGCvjZpVEnqdRmYom=
Koh5hlyo4GonBqe1eRKU4cC-2F-2FvtmUJsHFlaAVunmF9BPE4bs0e3Pqwz0-3D=0D
=0D
______________________=0D
If you would rather not receive future communications from UCB SA, please g=
o to https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jAT=
UeYfdhr1xEBQnaPhR2RKx1tfe2VKDZTewv5u80JomRcXeN-2FJ3N3FBIKfkZIG5jMSSyZ3ohHc9=
Efr9Jrat4eVGj2-2FAGfitZ6zqf1wMvC5QJi00Fh2u-2BMI-2F8ajICUilwOQWWeECsaYnPxDMi=
ApWdFJQyE-3DNvnM_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0=
KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wZEMZIHLafUIJL9IDButNV=
PltWMkFZCqcbfB7v6fXW0JW2ygGf2FYUXzy-2BAgRwQB-2BlDDi7B3TyL6dEl4SpM8RZYXQtsXS=
vkZU-2F4lZhuRWDVxnziKMYho9vKfPyYwwgWjEr10VFmQ43pGnVr3lMiuIe9-2BG2lPzMu1yorU=
Vgt0EnWPq31Nj4-2BDL6tJI2oYGXATHXPvn0IkadrHB4ATd8amZ-2BMU0QolfH7PqGqXe5G-2BJ=
Yw4UXdjri0eTtUF61zYopEgd0-3D=0D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=